I wanted to cite briefly the results of the TRIBE-2 study. This was an Italian phase III study that was led by the GONO group. We all participated in this very large trial. This trial is an honour for all Italy and will be presented tomorrow by Dr Chiara Cremolini, who is a friend of mine actually. This trial is very important because it’s setting a new standard for first and second line treatment of metastatic colorectal cancer patients independently of molecular selection.

So the study results are impressive since the primary study endpoint that was actually PFS2, meaning the time elapsed from randomisation to progressive disease on second line treatment, so this was a strategy trial, the primary endpoint was met. So I really think the option of FOLFOXIRI plus bevacizumab in the up-front setting is again confirmed, also, when considering post-progression treatment that may be given to our patients.